23 August 2016 - The MHRA has published EAMS scientific opinion on the use of pembrolizumab for metastatic non-small-cell lung cancer.

The early access to medicines scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.

The MHRA will give a scientific opinion on the benefit/risk balance of the medicine, based on the data available when the EAMS submission was made.

Read MHRA assessment report